Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -136.0%

Net margin was -136.0% in Q1 FY2026, down 27.6 pp from a year earlier. On a trailing-twelve-month basis it was -91.0%, up 2.0 pp year over year. Over 3 fiscal years it widened by 109.3 pp.

Context

  • Net margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 14 analysts of -17.6% for the fiscal year ending Dec 2026, up from -85.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-136.0%-73.7 pp QoQ
Last fiscal yearDec 2025
-85.4%+16.2 pp YoY
LTMMar 2026
-91.0%+2.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-27.6 pp-0.5 pp+27.0 pp
1 year+16.2 pp+67.8 pp+51.6 pp
3 years+109.3 pp+98.5 pp-10.8 pp
5 years+100.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-85.4%
Year-over-year change
+16.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's LTM Mar 2026 net margin of -91.0% is the 4th highest of the 10 companies compared; the peer median is -151.1%.
  • Its year-over-year change of +2.0 pp is the 4th highest of 8, against a peer median of -28.8 pp.
  • Over three fiscal years its change of +109.3 pp compares with a peer median of +304.7 pp.
RARE Competitors Peer median
Net Margin for RARE and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026454.9% —+4030.4 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-3.8% -39.5 pp+119.4 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-11.9% -28.8 pp+4.1 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-91.0% +2.0 pp+109.3 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-97.6% +231.6 pp+474.4 pp
MGTXMeiraGTx Holdings plcLTM Mar 2026-151.1% +333.8 pp+673.9 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-182.3% +766943.8 pp+3271.0 pp
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+134.9 pp
QUREuniQure N.V.LTM Mar 2026-1154.4% -77.4 pp-1116.9 pp
MREOMereo BioPharma Group plcLTM Mar 2026-7139.7% ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding RARE) -151.1%-28.8 pp+304.7 pp

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.41M363.33M434.25M560.23M673M
Cost of Revenue16.01M28.32M45.21M76.73M109M
Gross Profit335.4M335.01M389.04M483.5M564M
Gross Margin95.4%92.2%89.6%86.3%83.8%
Research & Development497.15M705.79M648.45M697.87M750M
Selling, General & Admin219.98M278.14M309.8M321.61M349M
Operating Expenses717.14M983.93M958.25M1.02B1.1B
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
EBITDA(410.32M)(640.49M)(516.45M)(469M)(474M)
EBITDA Margin-116.8%-176.3%-118.9%-83.7%-70.4%
Operating Income(381.74M)(648.92M)(569.21M)(535.97M)(535M)
Operating Margin-108.6%-178.6%-131.1%-95.7%-79.5%
Interest Income1.93M11.07M26.69M36.51M25M
Interest Expense29.42M43.02M66M63.04M62M
Other Income / Expenses(71.24M)(52.81M)(39.26M)(31.61M)(36M)
Income Before Tax(452.98M)(701.73M)(608.46M)(567.59M)(571M)
Pre-Tax Margin-128.9%-193.1%-140.1%-101.3%-84.8%
Income Tax Expense1.04M5.7M(1.83M)1.6M4M
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Net Margin-129.2%-194.7%-139.7%-101.6%-85.4%
EPS (Basic)(6.70)(10.12)(8.25)(6.29)(5.83)
EPS (Diluted)(6.70)(10.12)(8.25)(6.29)(5.83)
Weighted Avg Shares67.8M69.91M73.54M90.54M98.6M
Weighted Avg Shares (Diluted)67.8M69.91M73.54M90.54M98.6M

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.